OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kremyanskaya on the Efficacy of Rusfertide in Phlebotomy-Dependent Polycythemia Vera

June 16th 2023

Marina Kremyanskaya, MD, PhD, discusses key efficacy data for rusfertide in the phase 2 REVIVE trial of phlebotomy-dependent polycythemia vera.

Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL

June 16th 2023

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Dr Gupta on the 4-Year Efficacy of the EV-103 Trial in Urothelial Carcinoma

June 15th 2023

Shilpa Gupta, MD, discusses the 4-year safety and efficacy data derived from the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma.

Dr Hitchcock on the Rationale for the ERAsur Trial in Limited mCRC

June 15th 2023

Kathryn Hitchcock, MD, PhD, discusses the rationale for the ongoing phase 3 ERAsur trial investigating total ablative therapy in patients with limited metastatic colorectal cancer and details the methodologies being used in this study.

Dr Hutson on the Final OS Analysis of the CLEAR Study in Advanced RCC

June 15th 2023

Thomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.

Dr Elkhanany on Biological Drivers of Progression in ER+ Metastatic Breast Cancer

June 15th 2023

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches.

Dr Miron on Molecular Alterations in Intraductal Carcinoma of the Prostate

June 15th 2023

Benjamin Miron, MD, discusses findings and clinical implications from a study investigating molecular alterations in patients with intraductal carcinoma of the prostate.

Dr Burke on the Influence of the SHINE and TRIANGLE Trials on Ibrutinib Use in MCL

June 15th 2023

John M. Burke, MD, discusses the influence of two key BTK inhibitor combination studies on therapeutic approaches for patients with previously untreated mantle cell lymphoma.

Dr Bose on the Use of Zilurgisertib With/Without Ruxolitinib to Reduce Anemia in Myelofibrosis

June 15th 2023

Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis.

Dr Lee on the Investigation of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

June 15th 2023

Hans C. Lee, MD, discusses the investigation of the BCMA x CD3 bispecific antibody linvoseltamab in patients with relapsed/refractory multiple myeloma.

Franklin on the Effects of Social Determinants of Health on CRC Screening

June 14th 2023

Isabelle Franklin discusses the effects of social determinants of health on rates of colorectal cancer screening.

Dr Roloff on the Real-World Outcomes of Brexu-Cel in Relapsed/Refractory B-ALL

June 14th 2023

Gregory W. Roloff, MD, discusses real-world outcomes from treatment with brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Randall on One-stage Synovectomy in D-TGCT

June 14th 2023

R. Lor Randall, MD, FACS, discusses findings from a study of one-stage synovectomy in patients with diffuse-type tenosynovial giant cell tumor of the knee.

Dr Pemmaraju on Spleen Volume Reduction With Pacritinib in Myelofibrosis

June 14th 2023

Naveen Pemmaraju, MD, discusses the importance of introducing pacritinib (Vonjo) to the treatment paradigm for patients with myelofibrosis with low platelet counts.

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

June 14th 2023

Sachdev P. Thomas, MD, discusses the utility of the immunotherapy response score when predicting clinical benefit with pembrolizumab in advanced solid tumors.

Dr Giannakis on the Initial Efficacy of CGX1321 With or Without Pembrolizumab in GI Cancers

June 14th 2023

Marios Giannakis, MD, PhD, discusses preliminary efficacy data from a phase 1 study of CGX1321 with or without pembrolizumab in advanced gastrointestinal tumors.

Las Implicaciones del Estudo VIALE-A de Venetoclax Mas Azacitidina Para Paciente Inelegibles a Quimioterapia Intensiva

June 14th 2023

Nidia Zapata, MD, discusses the role of triplet therapy in the treatment of patients with acute myeloid leukemia.

Dr Masarova on the Rationale for Investigating Ropeginterferon Alfa-2b in Essential Thrombocythemia

June 13th 2023

Lucia Masarova, MD, discusses the single-arm multicenter phase 2 EXCEED-ET trial of ropeginterferon alfa-2b-njft in adult patients with essential thrombocythemia.

Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid Tumors

June 13th 2023

Bob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.

Dr Hamid on the Investigation of Fianlimab With Cemiplimab in Advanced Melanoma

June 13th 2023

Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.